BLUE (bluebird bio, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BLUE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-06-03 | Michael Cloonan | Director | D | — | — |
| 2025-06-03 | Mark Vachon | Director | MIXED | — | — |
| 2025-06-03 | John O Agwunobi | Director | MIXED | — | — |
| 2025-06-03 | Richard A. Paulson | Director | MIXED | — | — |
| 2025-06-03 | Najoh Tita-Reid | Director | MIXED | — | — |
| 2025-06-03 | O. James Sterling | Chief Financial Officer | MIXED | — | — |
| 2025-06-03 | Elisabeth Leiderman | Director | MIXED | — | — |
| 2025-06-03 | Nick Leschly | Director | MIXED | — | — |
| 2025-06-03 | Charlotte Jones-Burton | Director | MIXED | — | — |
| 2025-06-03 | Richard A Colvin | Chief Medical Officer | MIXED | — | — |
| 2025-06-03 | Andrew Obenshain | President and CEO | MIXED | — | — |
| 2025-06-03 | Thomas J Klima | See Remarks | MIXED | — | — |
| 2025-06-03 | Joseph Vittiglio | Chief Business & Legal Officer | MIXED | — | — |
| 2025-03-05 | Thomas J Klima | See Remarks | Sell | — | — |
| 2025-03-05 | Andrew Obenshain | President and CEO | Sell | — | — |
| 2025-03-05 | Richard A Colvin | Chief Medical Officer | Sell | — | — |
| 2025-02-12 | Andrew Obenshain | President and CEO | A | — | — |
| 2025-02-05 | Joseph Vittiglio | Chief Business & Legal Officer | Sell | — | — |
| 2025-02-05 | Richard A Colvin | Chief Medical Officer | Sell | — | — |
| 2025-02-05 | Thomas J Klima | See Remarks | Sell | — | — |
| 2025-02-05 | Andrew Obenshain | President and CEO | Sell | — | — |
| 2025-01-08 | Andrew Obenshain | President and CEO | Sell | — | — |
| 2025-01-08 | Richard A Colvin | Chief Medical Officer | Sell | — | — |
| 2024-12-12 | Andrew Obenshain | President and CEO | Sell | — | — |
| 2024-12-12 | Richard A Colvin | Chief Medical Officer | Sell | — | — |
| 2024-11-08 | Mark Vachon | Director | A | — | — |
| 2024-11-08 | John O Agwunobi | Director | A | — | — |
| 2024-11-08 | Charlotte Jones-Burton | Director | A | — | — |
| 2024-11-08 | Najoh Tita-Reid | Director | A | — | — |
| 2024-11-08 | Nick Leschly | Director | A | — | — |
| 2024-11-08 | Elisabeth Leiderman | Director | A | — | — |
| 2024-11-08 | Richard A. Paulson | Director | A | — | — |
| 2024-10-02 | Joseph Vittiglio | Chief Business & Legal Officer | A | — | — |
| 2024-10-02 | O. James Sterling | Chief Financial Officer | A | — | — |
| 2024-10-02 | Richard A Colvin | Chief Medical Officer | A | — | — |
| 2024-10-02 | Thomas J Klima | See Remarks | MIXED | — | — |
| 2024-10-02 | Andrew Obenshain | President and CEO | MIXED | — | — |
| 2024-10-02 | Michael Cloonan | Director | A | — | — |
| 2024-07-03 | O. James Sterling | Chief Financial Officer | A | — | — |
| 2024-06-24 | Michael Cloonan | Director | A | — | — |
| 2024-06-04 | Thomas J Klima | See Remarks | Sell | — | — |
| 2024-03-05 | Joseph Vittiglio | Chief Business & Legal Officer | A | — | — |
| 2024-03-05 | Christopher Krawtschuk | Chief Financial Officer | A | — | — |
| 2024-03-05 | Richard A Colvin | Chief Medical Officer | Sell | — | — |
| 2024-03-05 | Andrew Obenshain | President and CEO | Sell | — | — |
| 2024-03-05 | Thomas J Klima | See Remarks | Sell | — | — |
| 2024-02-06 | Andrew Obenshain | President and CEO | Sell | — | — |
| 2024-02-06 | Thomas J Klima | See Remarks | Sell | — | — |
| 2024-02-06 | Joseph Vittiglio | Chief Business & Legal Officer | Sell | — | — |
| 2024-01-09 | Andrew Obenshain | President and CEO | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 120,849 | — |
| — | 10%+ Owner | 112,718 | — |
| — | Director | 112,718 | — |
| — | 10%+ Owner | 89,679 | — |
| — | 10%+ Owner | 60,753 | — |
| — | Director | 57,756 | — |
| — | 10%+ Owner | 15,043 | — |
| — | Chief Strategy & Financial Off | 9,477 | — |
| — | President and CEO | 9,300 | — |
| — | Chief Financial Officer | 6,269 | — |
| — | Director | 5,466 | — |
| — | Director | 4,451 | — |
| — | Chief Business & Legal Officer | 3,125 | — |
| — | Chief Accounting Officer | 2,846 | — |
| — | Chief Medical Officer | 2,500 | — |
| — | Chief Medical Officer | 2,389 | — |
| — | Chief Financial Officer | 2,274 | — |
| — | Chief Regulatory Officer | 2,113 | — |
| — | Chief Strategy Officer | 2,071 | — |
| — | Chief Scientific Officer | 1,706 | — |
| — | Director | 1,323 | — |
| — | Chief Commercial Officer | 1,293 | — |
| — | Director | 1,245 | — |
| — | Director | 1,245 | — |
| — | Director | 1,245 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BLUE quote page; the site-wide leaderboard is on the insider transactions hub.